Meet our Management Team
Antibe’s senior team is based in Toronto, Canada. We are supported by a global network of advisors and subject matter experts covering scientific, clinical and regulatory affairs, and business development.
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures.
JD Queen’s University, Canada
Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
With his broad capital markets experience and informed by academic training in life sciences and computer engineering, Scott brings a unique perspective to funding and growing healthcare companies. His interest in the sector was sparked by the Human Genome Project, leading to his studies in biomedical computing.
General Management Program Harvard Business School, USA
MEng Computer Engineering University of Toronto, Canada
CFA® Charterholder (Chartered Financial Analyst)
“What struck me about Antibe from the beginning was that they were targeting a massive medical problem with a disruptive, best-in-class technology.”
CHIEF MEDICAL OFFICER
Following his medical training, Dr. Joseph (“Joe”) Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (FDA) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director.
DO Philadelphia College of Osteopathic Medicine, USA
Anesthesiology Residency The Johns Hopkins University School of Medicine, University Hospital, USA
MBA New York University, USA; London School of Economics, UK; Hautes Etudes Commerciales, France
College on Problems of Drug Dependence
Joe is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (“IMMPACT”), which became an official public-private partnership between pharmaceutical companies, the FDA, the National Institutes of Health, academia and patient advocacy organizations across the US.
“Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the later stages of clinical development.”
As a scientist and drug development executive, David has extensive experience in bringing drugs from early investigation to regulatory approval. Acting as a product development consultant for several major pharmaceutical firms, he has advanced treatments for bacterial infections and disorders of the central nervous and gastrointestinal systems.
|PhD Clinical Pathology and Biochemistry University of Toronto, Canada|
“I value the opportunity to develop a platform that validates a novel NSAID—a drug that can improve the quality of life for so many people suffering from daily pain.”
Alain is a seasoned CFO and consultant to private and public companies. He is a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies in challenging circumstances, such as extreme growth or a fundamental change in business model.
MBA International Institute for Management Development (IMD), Switzerland
BComm (Honours) Queen’s University, Canada
“I see Antibe’s mission in the context of my own family—my grandfather had major stomach surgery because of NSAIDs.”
With more than 20 years of capital markets experience in life sciences, Christina’s background includes positions in investment banking, equity sales and investor relations.
BBA Wilfred Laurier University, Canada
“At Antibe, what drives me is the dramatic difference our drugs could make to the lives of millions of patients.”
VP BUSINESS DEVELOPMENT
|A business development executive and scientist, Ella was most recently Vice President, Business Development for Advanced Proteome Therapeutics, a publicly traded biopharma company.
Earlier, she was Global Brand Manager for Nordion, where she was responsible for product marketing in the US and Asia. As Director of Business Development for IMV (NASDAQ: IMV), she spearheaded its critical licensing deal with Merck.
|MSc Medical Genetics University of Toronto, Canada
MBA Dalhousie University, Canada
Ella is founding CEO and director of TO Health!, a unique platform to convene the Toronto Region Health Cluster and develop the biotech sector — launched by the Toronto Region Board of Trade and incubated by MaRS Discovery District.
“When it comes to building strong partnerships, there’s no substitute for relationships, reputation and good data!”
A medical doctor with more than 15 years of driving global clinical projects and programs, Ana has managed studies across a variety of indications including pain, respiratory, rare and gastrointestinal diseases.
Ana is an expert in overseeing and coordinating the full suite of vendors and functions needed to carry out complex clinical trials, including CROs, labs, drug suppliers, data management, biostatistics, pharmacovigilance, regulatory, QA, legal and clinical monitoring.
MD University of Belgrade, Serbia
Ana was responsible for the set-up and management of the first fully virtual clinical trial by one of the world’s leading CROs.
“Executing Antibe’s clinical studies is my job—my medical degree and clinical development experience give me the tools I need to succeed!”
As a communicator and strategist, Philip has been contributing to the Antibe project since 2006. Over his career, he has been a senior advisor in pharma, dental products, medical devices, fintech, and a range of internet and IT technologies.
He is co-founder of Simon/Ross + Associates, which became the world’s leading Apple-focused computer training company, and a former lecturer in the Department of Computer Science at the University of Toronto.
MBA Harvard Business School, USA
BCom McGill University, Canada
Philip was co-founder and marketing head of Workfire Networks, a breakthrough internet infrastructure company acquired for $100 million by Packeteer.
“The year I began working with Antibe, my mom had emergency surgery because of NSAIDs … so this is personal!”